Verapamil therapy in infants with hypertrophic cardiomyopathy

Cardiology in the Young

Volumn 8, Issue 3, 1998, Pages 310-319

  Moran, Adrian M ^b   Colan, Steven D ^a  

^a Childrens Hospital   (United States)

^b NONE

Author keywords

Hypertrophic cardiomyopathy; Infants; Verapamil

Indexed keywords

VASODILATOR AGENT; VERAPAMIL;

ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEWBORN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CARDIOMYOPATHY, HYPERTROPHIC; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASODILATOR AGENTS; VERAPAMIL;

EID: 0032113264     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1047951100006818     Document Type: Article

References (43)

1. Maron BJ, Tajik AJ, Ruttenberg HD, Graham TP, Atwood GF, Victoria BE, Lie JT, Roberts WC. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circ 1982;65(1):7-17.
2. Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krickler S, Oakley CM. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;21(7):1672-1679.
3. Rosing DR, Kent KM, Maron BJ, Conduit J, Epstein SE. Verapamil therapy: a new approach to pharmacologic treatment of hypertrophic cardiomyopathy. Chest 1980;78:239-247.
4. Dabrowski M, Michalak E, Maurin A, Rydleweska-Sadowska W, Ruzyllo W. Results of long-term verapamil treatment of patients with hypertrophic cardiomyopathy. Kardiologia Polska 1989;32(Suppl 2):6-16.
5. Kober G, Hopf R, Biamino G, Bubenheimer P, Forster K, Kuck KM, Hanrath P, Van Olshausen KE, Schlepper M, Kaltenbach M. Long-term treatment of hypertrophic cardiomyopathy with verapamil or propranolol in matched pairs of patients: results of a multicenter study. Zeitschrift für Kardiologie 1987;76(Suppl 3):113-118.
6. Seiler C, Hess O, Schoenbeck M, Turina J, Jenni R, Turina M, Krayenbuehl HP. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective Study. J Am Coll Cardiol 1991;17(3):643-645.
7. Pelliccia F, Cianfrocca C, Romeo F, Reale A. Hypertrophic cardiomyopathy: long-term effects of propranolol versus verapamil in preventing sudden death in 'low risk' patients. Cardiovasc Drugs Ther 1990;4(6):1515-1518.
8. Gibson R, Driscoll D, Gillette P, Hartley C, Entman ML. The comparative electrophysiologic and haemodynamic effects of verapamil in puppies and adult dogs. Dev Pharmacol Ther 1981;2:104-116.
9. Porter CJ, Garson A Jr, Gillette PC. Verapamil: an effective calcium blocking agent for pediatric patients. Pediatrics 1983;71:748-755.
10. Roguin N, Shapir Y, Kaplinsky E. The Use of Calcium Gluconate Prior to Verapamil in Infants With Paroxysmal Supraventricular Tachycardia. Springer, New York, 1985: 105.
11. Radford D. Side effects of verapamil in infants. Arch Dis Child 1983;58:465-466.
12. Colan SD, Parness IA, Spevak PJ, Sanders SR Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 1992;19:619-629.
13. Colan SD, Boutin C, Castaneda AR, Wernovsky G. Status of the left ventricle after arterial switch operation for transposition of the great arteries: haemodynamic and echocardiographic evaluation. J Thorac Cardiovasc Surg 1995;109:311-321.
14. Odemuyiwa O, McKenna WJ. Problems in diagnosis and management of hypertrophic cardiomyopathy. Postgrad Med J 1991; 67:713-718.
15. Burch M, Sharland M, Shinebourne E, Smith G, Patton M, McKenna W. Cardiologic abnoralities in Noonan syndrome: phenotypic diagnosis and echocardiographic assessment of 118 patients. J Am Coll Cardiol 1993;22:1189-1192.
16. Burch M, Mann JM, Sharland M, Shinebourne EA, Patton MA, McKenna WJ. Myocardial disarray in Noonan syndrome. Br Heart J 1992;68(6):586-588.
17. Arai S, Matsuoka R, Hirayama K, Sakurai H, Tamura M, Ozawa T, Kimura M, Imamura S, Furutani Y, Joh-o K et al. Missense mutation of the beta-cardiac myosin heavy-chain gene in hypertrophic cardiomyopathy. Am J Med Genet 1995;58(3):267-275.
18. Suda K, Kohl T, Kovalchin JR. Silverman NH. Echocardiographic predictors of poor outcome in infants with hypertrophic cardiomyopathy. Am J Cardiol 1977;80:595-600.
19. Walsh ER Electrocardiography and introduction to electrophysiologic techniques. In Fyler D (ed.), Nadas' Pediatric Cardiology. Hanley & Belfus, Philadelphia, 1992: 137-138.
20. Martin AB, Garson A Jr, Perry J. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J 1994;127(1):64-70.
21. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circ 1981;64(3):437-44l.
22. Somerville J, Becu L. Congenital heart disease associated with hypertrophic cardiomyopathy. B Heart J 1978;40(9):1034-1039.
23. Guenthard J, Wyler F, Fowler B, Baumgartner R. Cardiomyopathy in respiratory chain disorders. Arch Dis Child 1995;72(3):223-226.
24. Werner JC, Sicard RE, Hansen TW, Solomon E, Cowett RM, Oh W Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 1992;120:286-291.
25. Bobele GB, Ward KE, Bodensteiner JB. Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study. Am J Dis Child 1993;147(2):223-225.
26. Reller MD, Kaplan S. Hypertrophic cardiomyopathy in infants of diabetic mothers: an update. Am J Perinatol 1988;5(4):353-358.
27. Garson A Jr. Medicolegal Problems in the management of cardiac arrhythmias in children. Pediatrics 1987;79(1):84-88.
28. TenCate FJ, Serruys PW, Mey S, Roelandt J. Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined haemodynamicultrasonic technique in patients with hypertrophic cardiomyopathy. Circ 1983;68(6):1274-1279.
29. Bonow RO, Ostrow HG, Rosing DR, Cannon RO, Lipson LC, Maron BJ, Kent KM, Bacharach SL, Green MV Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a non-imaging scintillation probe. Circ 1983;68(5):1062-1073.
30. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. Circ 1979;60(6):1201-1207.
31. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986;315:610-614.
32. Panza JA, Maris TJ, Maron BJ. Development and determinants of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. Circ 1992;85:1398-1405.
33. Chatterjee K, Raff G, Anderson D, Parmley WW. Hypertrophic cardiomyopathy-therapy with slow channel inhibiting agents. Prog Cardiovasc Dis 1982;25(3):193-210.
34. Spicer RL, Rocchini AP, Crowley DC, Rosenthal A. Chronic verapamil therapy in pediatric and young adults patients with hypertrophic cardiomyopathy. Am J Cardiol 1984;53(11):1614-1619.
35. Meyer M, de Moor MM, Human D. Hypertrophic cardiomyopathy in infancy and childhood. S Af Med J 1987;71(8):490-493.
36. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11(1):147-153.
37. Maron BJ, Henry WL, Clark CE, Redwood DR, Roberts WC, Epstein SE. Asymmetric septal hypertrophy in childhood. Circ 1976;53(1):9-19.
38. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47(3):532-538.
39. Fiddler GI, Tajik AJ, Weidman W, McGoon DC, Ritter DG, Giuliani ER. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol 1978;42(5):793-799.
40. Maron BJ, Henry WL, Clark CE, Redwood DR, Roberts WC, Epstein SE. Asymetric septal hypertrophy in childhood. Circ 1976;53(1):9-19.
41. Maron BJ, Bonow RO, Cannon RO 3d, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathology and therapy. N Eng J Med 1987;316:780-789, 844-852.
42. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognositic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981;48(2):252-257.
43. Davies MJ, Krikler DM. Genetic investigation and counselling of families with hypertrophic a cardiomyopathy. Br Heart J 1994;72(2):99-101.